Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1
Per the paper, the implication from all the available evidence is that "Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19 who were treated concurrently with other available therapies"2
Results of the LIVE-AIR Phase 3 trial demonstrate treatment of hospitalized COVID-19 patients with lenzilumab results in a statistically significant 54% relative improvement in the likelihood of survival without the need for invasive mechanical ventilation ("SWOV")
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.